Register or Sign in to Save this opportunity, or Send an Inquiry.
Regulatory Dendritic Cell-Based Rheumatoid Arthritis Vaccine Technology_CreaGene Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Rheumatoid arthritis treatment using dendritic cells
Send an Inquiry

Technology Overview

1. Background of Technology

1) Rheumatoid Arthritis treatment CreaVax-RA

Rheumatoid arthritis (RA) is an abnormal immune response and one of the autoimmune disease in which the thin synovial tissue surrounding joints are filled with leukocytes to cause continuous inflammation. Secreted cytokines or other elements cause an abnormal increase in FLSs (fibroblast-like synoviocytes) to create a hyper layer of synovial cells, known as pannus. This is a systemic disease which infiltrates surrounding cartilage and bones to cause cartilage/bone damage. While the initial pathological diagnosis is focused on joints, it is a serious disease which spreads over the entire body with time.

Non-steroidal anti-inflammatory drugs (NSAIDS) and Disease modifying anti-rheumatic drugs (DMARDS) are widely used to treat Rheumatoid arthritis. Yet such forms of treatment cannot prevent or delay the progression of the disease and work only to relieve arthritic pain and edema. As a result, it is a priority to develop a new form of treatment which can overcome the limitations of current Rheumatoid arthritis treatments.

Creagene is actively conducting research and development for permanent forms of treatment using dendritic cells as well as gene-based treatments for over-expressed genes in patients suffering from Rheumatoid arthritis by customizing to its autoimmune disease characteristics.

2. Description on Technology Applied

1) Rheumatoid Arthritis treatment using dendritic cells (CreaVax-RA)

(A) Types of Dendritic cell

Dendritic cells can be classified into mature DC and immature DC according to levels of differentiation. Mature DC induces immune responses and is used to treat tumors, whereas immature DC are known to be control to immune tolerance and immune regulation.  In addition, semi-mature DC exposed to arthritis antigens for short periods of time are known for antigen specific immune suppression rather than immune activities as they show lower manifestation levels of co-stimulatory molecules.

(B) iTreatment of Rheumatoid arthritis through use of immune tolerant dendritic cells

Creagene has used mature DC to develop cancer treatments while semi-mature DC are used to treat autoimmune diseases, such as for Rheumatoid arthritis. In addition, MSCs (mesenchymal stem cells), which induce strong immune suppression, can be used together with dendritic cells to induce more effective immune tolerance.

Creagene has technologies for the production of immune treatments which utilize dendritic cells from bone marrow as well as related pre-clinical and clinical experience and technologies. Based on such foundation, the company has been developing a type of Rheumatoid arthritis treatment which utilizes immature or semi-mature dendritic cells. In addition, the powerful immune suppressive effects of immature dendritic cells are expected to be utilized not only within autoimmune diseases, but also for organ transplants.

3. Differential Point, Superiority or Characteristics of Technology Applied

Rheumatoid arthritis treatments utilizing dendritic cells treat rheumatoid arthritis through antigen specific immune suppression without affecting normal cells. Rheumatoid arthritis treatment utilizing dendritic cells have no toxicity or side effects. More than just reducing arthritic pain and edema, the treatment is a fundamental treatment for rheumatoid through the immune suppression effects of dendritic cells.

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833